טוען...
Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma
Drug resistance remains the key problem in cancer treatment. It is now accepted that each myeloma patient harbors multiple subclones and subclone dominance may change over time. The coexistence of multiple subclones with high or low chromosomal instability (CIN) signature causes heterogeneity and dr...
שמור ב:
| הוצא לאור ב: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026005/ https://ncbi.nlm.nih.gov/pubmed/29863498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI98765 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|